Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 13/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 10/20 | 0.35 |
| ▸ | FAP | Q12884 | 8/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.35 |
| ▸ | PREP | P48147 | 5/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8227865 | 0.82 | ACE (0.41) | F2 | |
| SCHEMBL85497 | 0.82 | ACE (0.41) | F2 | |
| SCHEMBL11990391 | 0.82 | ACE (0.41) | F2 | |
| SCHEMBL11990508 | 0.82 | DPP4 (0.33) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL415470 | 0.77 | POLB (0.45) | SMN1; SMN2 | |
| SCHEMBL12288846 | 0.76 | ALDH1A1 (0.39) | SMN1; SMN2F2ALDH1A1 | |
| SCHEMBL11990446 | 0.76 | ALDH1A1 (0.39) | SMN1; SMN2F2ALDH1A1 | |
| SCHEMBL11990379 | 0.76 | ALDH1A1 (0.39) | SMN1; SMN2F2ALDH1A1 | |
| SCHEMBL13541999 | 0.74 | SMN1; SMN2 (0.32) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL6505632 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170129916-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2017-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129916-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | BET1, PRR12, PREP | DPP4 480/4885DPP7 255/4885FAP 1637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.